SABS

+ Watchlist + Portfolio

SAB Biotherapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.78
52-Week Range: $1.85 – $5.15
Market Cap: $336.65M
P/E (TTM): 15.42
EPS (TTM): 0.24
Dividend Yield: —

Advanced Metrics

Price/Book: 1.44
PEG Ratio: —
Return on Equity: -11.27%
Return on Assets: -33.46%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 9.22
Debt/Equity: 0.02
Total Debt: $5.13M
Free Cash Flow: $-28.84M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $246.43M

SABS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$36.44M	$16.52M	$30.25M	$34.35M
Selling, General & Admin	$16.38M	$23.80M	$13.98M	$14.60M
Operating Expenses	$28.92M	$38.08M	$42.91M	$48.95M
Operating Income	-$28.92M	-$38.08M	-$42.91M	-$48.95M
EBITDA	-$15.12M	-$38.13M	-$28.99M	$16.60M
Pretax Income	-$18.72M	-$42.19M	-$34.11M	$13.27M
Income Tax	$25.63K	$0.00	—	—
Net Income	-$18.74M	-$42.19M	-$34.11M	$13.27M
Diluted EPS	-4.31	-7.64	-3.68	-0.79
Diluted Shares	4.35M	5.52M	9.26M	61.34M

SABS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$15.05M	$56.57M	$8.90M	$10.50M
Receivables	$5.56M	$0.00	$54.95K	$946.78K
Current Assets	$22.10M	$58.91M	$23.79M	$101.05M
Total Assets	$50.90M	$83.94M	$44.20M	$172.81M
Current Liabilities	$14.99M	$10.81M	$7.98M	$10.68M
Long-Term Debt	$541.64K	—	—	—
Total Debt	$5.93M	$5.91M	$4.67M	$5.95M
Total Liabilities	$19.85M	$26.64M	$18.23M	$21.32M
Retained Earnings	-$47.87M	-$90.06M	-$124.17M	-$110.90M
Shareholders' Equity	$31.06M	$57.30M	$25.97M	$151.49M
Working Capital	$7.10M	$48.09M	$15.81M	$90.37M

SABS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$23.46M	-$25.12M	-$34.29M	-$44.78M
Capital Expenditure	-$2.17M	-$197.15K	-$337.26K	-$933.16K
Free Cash Flow	-$25.63M	-$25.32M	-$34.63M	-$45.71M
Depreciation & Amortisation	$3.29M	$3.75M	$4.79M	$3.08M
Stock-Based Compensation	$2.67M	$2.42M	$2.94M	$5.21M
Investing Cash Flow	-$2.09M	-$152.70K	-$11.96M	-$121.71M
Financing Cash Flow	$1.05M	$66.77M	-$1.17M	$168.30M
Share Repurchases	-$5.52M	$0.00	—	—
Net Change in Cash	-$24.50M	$41.50M	-$47.43M	$1.82M

SABS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.66M	$7.00M	$8.97M	$10.73M	$13.40M
Selling, General & Admin	$3.11M	$2.74M	$3.71M	$5.04M	$6.60M
Operating Expenses	$10.77M	$9.73M	$12.68M	$15.77M	$20.00M
Operating Income	-$10.77M	-$9.73M	-$12.68M	-$15.77M	-$20.00M
EBITDA	-$4.35M	-$9.28M	$46.25M	-$16.03M	-$18.05M
Pretax Income	-$5.20M	-$10.11M	$45.45M	-$16.86M	-$18.87M
Net Income	-$5.20M	-$10.11M	$45.45M	-$16.86M	-$18.87M
Diluted EPS	-0.56	-1.09	-0.21	—	-0.35
Diluted Shares	9.29M	9.29M	77.86M	—	53.56M

SABS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.64M	$3.69M	$29.42M	$10.50M	$20.52M
Receivables	$21.39K	$0.00	$559.95K	$946.78K	$1.56M
Current Assets	$16.30M	$9.31M	$113.28M	$101.05M	$112.78M
Total Assets	$38.12M	$30.13M	$183.45M	$172.81M	$248.47M
Current Liabilities	$9.65M	$10.68M	$10.79M	$10.68M	$9.85M
Total Debt	$6.78M	$6.42M	$6.19M	$5.95M	$6.17M
Total Liabilities	$16.71M	$18.11M	$18.37M	$21.32M	$21.22M
Retained Earnings	-$129.37M	-$139.48M	-$94.03M	-$110.90M	-$129.76M
Shareholders' Equity	$21.41M	$12.02M	$165.07M	$151.49M	$227.25M
Working Capital	$6.64M	-$1.37M	$102.48M	$90.37M	$102.93M

SABS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.80M	-$7.15M	-$13.05M	-$16.78M	-$14.27M
Capital Expenditure	—	—	—	—	-$983.26K
Free Cash Flow	-$7.80M	-$7.15M	-$13.05M	-$17.71M	-$15.25M
Depreciation & Amortisation	$778.30K	$774.52K	$765.47K	$763.30K	$752.67K
Stock-Based Compensation	$612.95K	$627.20K	$800.76K	$3.17M	$5.46M
Investing Cash Flow	$4.67M	$5.20M	-$129.87M	-$1.71M	-$65.65M
Financing Cash Flow	-$173.99K	-$173.84K	$168.69M	-$41.69K	$89.92M
Net Change in Cash	-$3.30M	-$2.13M	$25.77M	-$18.52M	$10.00M

Market Snapshot

About

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal antibody therapeutics using its proprietary DiversitAb platform. The company genetically engineers cattle to produce fully human antibodies that can target a wide range of infectious diseases, cancer, and autoimmune disorders. SAB Biotherapeutics has developed therapeutic candidates for diseases including COVID-19, influenza, and other emerging infectious threats.